Connect with us

Business Wire

The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds Promise as a New Treatment Option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)

Business Wire



Reading Time: 2 minutes

PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Xcovery Holdings, Inc., an oncology-focused biopharmaceutical company, today announced that ensartinib, the company’s lead drug candidate, demonstrated efficacy and safety in patients with crizotinib-refractory, anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), including those with brain metastases. The peer-reviewed manuscript of the study, “Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial” was published online in The Lancet Respiratory Medicine.

“These results from the ensartinib China registration trial are very encouraging. They support our ongoing global phase 3 efforts in evaluating ensartinib’s efficacy and safety in the first line setting,” said Li Mao, M.D., Chief Executive Officer of Xcovery, “Our company is dedicated to developing drugs to help cancer patients and we believe ensartinib has the potential to be the best-in-class first line therapy for ALK-positive NSCLC patients.”

The multicenter phase 2 registration study analyzed the efficacy and safety of ensartinib in ALK-positive NSCLC patients that failed prior crizotinib treatment. The study also explored the associations between ensartinib efficacy and crizotinib-resistant mutations.

Ensartinib showed very promising activity in patients with ALK-positive NSCLC whose disease had progressed on previous crizotinib therapy. 52% (95% CI 43–60) of patients had a systemic objective response, whereas 70% (53–83) had an intracranial objective response, as assessed by an independent review committee.

In the study, most treatment-related adverse events were grade 1 or 2 and low proportions of patients required dose modifications or discontinued. Ensartinib also demonstrated activity against a broad array of ALK mutations, including G1202R, G1269A, F1174, C1156Y, and T1151.

D. Ross Camidge, M.D., from the University Of Colorado Department Of Medicine provided the Editorial Comment for the Lancet published study. “The median progression-free survival associated with ensartinib (9.6 months) was remarkably similar to that reported for the same drug at the same dose in a separate US study (9.2 months),” noted Dr. Camidge. “Cross-trial comparison would suggest that ensartinib’s activity is thus likely to be similar, if not marginally superior, to that of alectinib.”

“This data set supports ensartinib as a new option for ALK-positive NSCLC patients in a refractory setting,” said Giovanni Selvaggi, M.D., Chief Medical Officer at Xcovery and co-author of the study. “The high efficacy against brain metastases and the encouraging signal in resistant mutations, including G1202R, make ensartinib a promising treatment in an area where there is still significant unmet medical need.”

To view the article, please visit

For more information on the ensartinib phase 3 clinical trial, please visit

About Ensartinib

Ensartinib (X-396) is a potent anaplastic lymphoma kinase (ALK) inhibitor currently in a global phase 3 trial for ALK-positive NSCLC in the first line.

About Xcovery

Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors. For more information, visit

Forward‐Looking Statements

This press release contains forward‐looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.


Xcovery Holdings, Inc.
Kevin Sang

Chief Operating Officer

(561) 835-9356

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.

Business Wire

SAIC Wins U.S. Army Human Resources Command Cloud Contract

Business Wire



Reading Time: 3 minutes

Company will assess, modernize, and migrate 89 Army Human Resources applications to a commercial cloud solution.

RESTON, Va.–(BUSINESS WIRE)–The U.S. Army selected Science Applications International Corp. (NYSE: SAIC) to modernize its information technology (IT) infrastructure by migrating enterprise applications to a cloud environment. The Army Human Resources Command Cloud Computing Environment (HRC2E) contract is worth more than $41 million over three years and was competed under the Information Technology Enterprise Solutions – 3 Services (ITES-3S) contract.

“We are excited and pleased to work with the Army/HRC to modernize their legacy systems and help steward their applications to a cloud environment. This initiative is a critical step towards the Army’s goal to capitalize on cost savings, agility, and innovations as they successfully transition into a commercial cloud environment,” said Jim Scanlon, SAIC executive vice president and general manager of the Defense Systems Customer Group.

The contract calls for SAIC to assess, modernize, and migrate 89 Army Human Resource applications to a commercial cloud solution. By modernizing its IT, the Army will refactor, re-architect, rebuild and/or replace internal application components, which results in improved cybersecurity and application performance, lower total cost of ownership, and/or lower operations and maintenance costs.

“This new contract is another important step in SAIC’s efforts to deliver first-class IT modernization solutions to the U.S. government,” said Coby Holloway, SAIC vice president of IT Modernization. “By helping our customers on their digital transformation journey to make use of the best technology has to offer, we’re empowering the Army and others to focus on what matters most — delivering outstanding mission outcomes.”

About SAIC

SAIC® is a premier technology integrator solving our nation’s most complex modernization and readiness challenges. Our robust portfolio of offerings across the defense, space, civilian, and intelligence markets includes high-end solutions in engineering, IT, and mission solutions. Using our expertise and understanding of existing and emerging technologies, we integrate the best components from our own portfolio and our partner ecosystem to deliver innovative, effective, and efficient solutions.

We are 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has pro forma annual revenues of approximately $6.5 billion. For more information, visit For ongoing news, please visit our newsroom.

Forward-Looking Statements

Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at or on the SEC’s website at Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.


SAIC Media Contact:
Lauren Presti


Continue Reading

Business Wire

Direct Contracting with Employers for Health Care: Henry Ford Health System Shares Insights on Ground-breaking Program with General Motors

Business Wire



Reading Time: 3 minutes

Council of Accountable Physician Practices Principles Undergird Historic Partnership

WASHINGTON–(BUSINESS WIRE)–#NatAllForum–A panel discussion on lessons learned in direct contracting at the National Alliance of Healthcare Purchasers’ Annual Forum in Washington, D.C. provided insight into the “direct to employer” healthcare contract announced last year between Henry Ford Health System and General Motors.

Chelsea Pollet, director of Direct-to-Employer Relationships at Henry Ford, participated in the Nov. 12 panel discussion and spoke of how patient experience, quality of care and care management served as the foundation for the agreement.

Henry Ford is an active participant in the Council of Accountable Physician Practices (CAPP), a coalition of visionary medical groups and health systems that support integrated health care delivery.

“The CAPP pillars of care coordination, connected technology, evidence-based treatment decisions, physician leadership and pay-for-performance are the underpinnings of the Henry Ford-GM program,” noted Stephen Parodi, M.D., Chairman of CAPP and Associate Executive Director of The Permanente Medical Group. “These principles are shared by the 30-plus members of CAPP, which together include more than 80,000 physicians. When these concepts are incorporated into health care delivery, quality goes up and costs are better managed.”

“Our experience in other risk-based contracts, including Next Generation ACO and Medicare Advantage, was critical in preparing us to design a program that directly served the needs of GM salaried employees and their families,” Pollet said. “We approached the agreement as a slightly different way to do population health. We worked with GM to determine what was most important to them and their workforce. We knew from our experience with risk-based contracts that we could have success implementing value-based care.”

Pollet said three areas emerged as being of significant value to GM and helped shape the program’s design:

  • Delivering a seamless customer experience. For GM members who chose the “ConnectedCare” plan option, Henry Ford created a dedicated concierge call center.
  • Innovative and coordinated care management. The concept of customer experience went beyond the employee-facing services and encompassed the patient’s entire journey, including care navigation for episodes of illness and changes in health status. With a healthy, commercial population, Henry Ford created new ways to perform care management.
  • Expansive network. The Henry Ford Physician Network expanded to meet network adequacy requirements, ensuring that GM employees and their families eligible for “ConnectedCare” had access to care.

Pollet noted that the program was a first for both Henry Ford and GM, and required a high degree of collaboration, transparency and mutual learning. Having clear goals, an understanding of the population, and certain plan design elements in place were essential. She said collaborative teamwork was the key ingredient for success.

Additional panelists included Bob McCollins, Managing Director, Employers’ Advanced Cooperative on Healthcare; Gary Rost, Executive Director, Savannah Business Group; and Peter Hayes, President and CEO, Healthcare Purchaser Alliance of Maine.

About the Council of Accountable Physician Practices

The Council of Accountable Physician Practices (CAPP), an affiliate of the AMGA Foundation, is a coalition of visionary medical group and health system leaders. CAPP believes that physicians working together, backed by integrated services, systems and data and technology, can best shape and guide the way care is delivered so that the welfare of the patient is always the primary focus. For more information, contact CAPP at


Joy Scott, CEO, Scott Public Relations
Phone: 818.610.0270

Continue Reading

Business Wire

1st Detect’s Tracer 1000™ Deployed in Live Screening at Miami International Airport

Business Wire



Reading Time: 2 minutes

AUSTIN, Texas–(BUSINESS WIRE)–Astrotech Corporation’s (NASDAQ: ASTC) 1st Detect subsidiary announced today that it was selected by the U.S. Department of Homeland Security (DHS) Transportation Security Administration (TSA) to conduct live screening with the TRACER 1000™ at Miami International Airport. The invitation was in response to the TSA Innovation Task Force (ITF) Innovative Demonstrations for Enterprise Advancement (IDEA) Broad Agency Announcement (BAA).

The ITF works in partnership with airports, airlines, and industry partners to foster innovation in aviation security. It was created to help find and deploy the very best technology for increasing security and improving the passenger experience. The ITF enables accelerated productization of innovative new technologies by deploying products in real-world environments and allowing for the collection of valuable operational field data and feedback.

“We are excited to be part of TSA’s ITF program that introduces cutting edge technologies to live environments in the United States. This testing will help us further refine our product as we continue through the TSA certification and qualification process,” stated Raj Mellacheruvu, Chief Executive Officer of 1st Detect. “Much like their counterparts the world over, we are confident that the security personnel at Miami International Airport will be pleased with the ability of the Tracer 1000 to detect explosives with near-zero false alarms, its low cost of ownership, and its near 100% operational uptime.”

About Astrotech Corporation

Astrotech (NASDAQ: ASTC) is a science and technology development and commercialization company that launches, manages, and builds scalable companies based on innovative technology in order to maximize shareholder value. 1st Detect develops, manufactures, and sells explosives and narcotics trace detectors for use in the security and detection markets. Astrotech is headquartered in Austin, Texas. For information, please visit

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, whether we can successfully develop our proprietary technologies and whether the market will accept our products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.


Eric Stober, Chief Financial Officer, Astrotech Corporation, (512) 485-9530


Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets


Please turn AdBlock off